Search

Your search keyword '"You, B"' showing total 1,601 results

Search Constraints

Start Over You searched for: Author "You, B" Remove constraint Author: "You, B"
1,601 results on '"You, B"'

Search Results

1. Structural origin of the Jeff=1/2 antiferromagnetic phase in Ga-doped Sr2IrO4

2. Strain tuned magnetotransport of Jeff=1/2 antiferromagnetic Sr2IrO4 thin films

3. Wavelet analysis of MAXI J1535-571 with Insight-HXMT

4. Antiferromagnetic multi-level memristor using linear magnetoelectricity

7. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

8. RNA Modifications Meet Tumors

9. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

12. Electric field Control of Exchange Bias by Resistive Switching

13. The properties of active galaxies at the extreme of eigenvector 1

14. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro.

16. The appearance of non-spherical systems. Application to LMXB

17. SALT long-slit spectroscopy of HE 0435-4312: fast displacement in the Mg II emission line

18. The mass of the black hole in RE J1034+396

19. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

20. Enfermedades trofoblásticas gestacionales: molas hidatiformes

21. Spin and orbital moments of nanoscale Fe3O4 epitaxial thin film on MgO/GaAs(100)

22. Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups

23. Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE

24. THE OPTICAL VARIABILITY of SDSS QUASARS from MULTI-EPOCH SPECTROSCOPY. III. A SUDDEN UV CUTOFF in QUASAR SDSS J2317+0005

26. Impact of molecular genotyping on the diagnosis and treatment of human chorionic gonadotropin-producing tumors.

27. High-Performance Overall Water Splitting Electrocatalysts Derived from Cobalt-Based Metal-Organic Frameworks

28. Bimetal-Organic Framework Self-Adjusted Synthesis of Support-Free Nonprecious Electrocatalysts for Efficient Oxygen Reduction

29. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells

30. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)

31. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology

32. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

33. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa

34. Electronically Guided Self Assembly within Quantum Corrals

35. Spin Hall Angle Quantification from Spin Pumping and Microwave Photoresistance

36. LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial

37. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

39. A low noise 2.2 GHz PLL ASIC for the CSR external-target experiment

40. 36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial

41. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

43. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

49. Tratamiento médico de los cánceres epiteliales de ovario

Catalog

Books, media, physical & digital resources